Mannkind: Overlooked Biotech With Excellent Prospects (Part II)

Part II: Pfizer’s (PFE) cancer announcement and its irrelevance to Mannkind’s (MNKD) future 

As I explained in detail in Part 1 of this series (see here if you missed it), Mannkind has a potential home run with Technosphere Insulin, their upcoming drug for diabetes. Technosphere Insulin is an inhaled insulin which is more convenient for patients and, more importantly, has significant medical advantages. It has lower rates of hypoglycemia (dangerously low levels of blood sugar) than conventional injected insulin, and promotes weight loss instead of the weight gain common with conventional insulin.